A Phase 2/3 interventional study of Zavegepant (BHV-3500) and Placebo in COVID-19 Infection, sponsored by Pfizer. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-02.
Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in COVID-19 by Pfizer — 4 open to participants now, 10 under way, 3 of them phase 3. COVID-19 · Pfizer.
Among the 69 studies in COVID-19 by Pfizer, this one is the 15th largest by enrollment of the 41 interventional ones that give a count, is one of 3 that started in 2020, is one of 4 in phase 2/3, and was the 1st registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →4 of the 69 studies in COVID-19 by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Argentina, Belgium and 15 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Belgium and 16 more countries
Ages 12+
Pfizer · Sites in Korea, Republic of
Ages 19+
Pfizer · Sites in United States, Bulgaria, Japan and 4 more countries
Ages 0–17
By country, each count listing its studies:
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 11 · Phase 3 8 · Phase 4 1
First in 2020; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is below the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 20 across the 41 interventional studies, 2,038 across the 28 observational. Of the 53 that completed or were terminated, 39 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
5 of the studies in COVID-19 by Pfizer that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT06613984PfizerKorean Post Marketing Surveillance for Comirnaty Injection (Bretovameran) | 2026-12-30 |
| NCT05032976PfizerKorea Comirnaty Post-marketing Surveillance | 2027-01-24 |
| NCT05160636PfizerA Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza | 2027-01-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies in COVID-19 by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if a CGRP receptor antagonist may potentially blunt the severe inflammatory response at the alveolar level, delaying or reversing the path towards oxygen desaturation, Acute respiratory distress syndrome (ARDS), requirement for supplemental oxygenation, artificial ventilation or death in patients with COVID-19 on supplemental oxygen.
* BHV-3500, formerly "vazegepant", is now referred to as "zavegepant" (za ve' je pant). The World Health Organization (WHO) International Nonproprietary Names (INN) Expert Committee revised the name to "zavegepant" which was accepted by the United States Adopted Names (USAN ) Council for use in the U.S. and is pending formal adoption by the INN for international use.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Zavegepant (BHV-3500) 10 mg intranasal (IN) dosed every 8 hours (3 times/day) (Q8h) for 14 days
Drug: Zavegepant (BHV-3500)
Placebo Q8h for 14 days Subjects dosed every 8 hours; 3 times/day (Q8h)
Drug: Placebo
10 mg intranasal (IN) for 14 days
Placebo Q8h for 14 days
Mean 6 Point Ordinal Severity Rating Scale (6POSRS) Score at Day 15
The 6POSRS score was used to assess severity and ranged from 1 to 6 where: 1= Death; 2= Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO), 3= Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 4= Hospitalized, requiring supplemental oxygen; 5= Hospitalized, not requiring supplemental oxygen and 6= not hospitalized. A higher score indicated a better outcome.
Time frame: Day 15
Percentage of Participants With a 6-Point Severity Rating of 5 or 6, Who Were Alive and Off Supplemental Oxygen at Day 29
Percentage of participants who were alive and had a 6POSRS rating of 5 (Hospitalized, not requiring supplemental oxygen) or 6 (not hospitalized) and did not use supplemental oxygen at Day 29 were reported in this outcome measure. Participants with missing 6POSRS rating at Day 29 had the last on-study 6POSRS rating before Day 29 used. Participants with \>= 1 procedure day of supplemental oxygen use before Day 29 for an ongoing procedure were considered failures, i.e., not alive or not off of oxygen at Day 29. 95% confidence interval (CI) was based on exact Clopper and Pearson method.
Time frame: Day 29
Percentage of Participants With a 6-Point Severity Rating of 2 or 3 or Required Initiation of Invasive Mechanical Ventilation, Non-Invasive Ventilation, or a High-Flow Nasal Cannula Through Day 29
Percentage of participants who had a 6POSRS rating of 2 (Hospitalized, on invasive mechanical ventilation or ECMO) or 3 (Hospitalized, on non-invasive ventilation or high-flow oxygen devices) or \>= 1 procedure day of ventilation or high-flow nasal cannula use on study through Day 29 were reported in this outcome measure. Participants with missing 6POSRS rating at Day 29 had all available on-study 6POSRS ratings before Day 29 used. 95% CI was based on exact Clopper and Pearson method.
Time frame: Up to Day 29
Percentage of Participants Admitted Into an Intensive Care Unit (ICU) Through Day 29
Percentage of participants admitted into an ICU on any day through Day 29 were reported in this outcome measure. 95% CI was based on exact Clopper and Pearson method
Time frame: Up to Day 29
Number of Participants With On-Treatment Deaths, Serious Adverse Events (SAEs) and Severe Adverse Events (AEs)
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was any untoward medical occurrence that at any dose: resulted in death; was life-threatening; required prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect; other important medical events. Severe AEs were AEs that interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. On-treatment was defined as the time on study drug.
Time frame: From first dose of study treatment on Day 1 until Day 15
Number of Participants With Grade 3 or 4 On-Treatment Laboratory Test Abnormalities
The following laboratory parameters were assessed: eosinophils, hemoglobin, leukocytes, lymphocytes (high and low), neutrophils, platelets, alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium (high and low), creatine kinase, creatinine, glomerular filtration rate (GFR) estimated Modification of Diet in Renal Disease (MDRD), glucose (high and low), lactate dehydrogenase, potassium (high and low), sodium (high and low), urate, glucose (urine) and protein (urine). Laboratory abnormalities were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5 for all parameters except glucose and uric acid. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1 was used for grading glucose and uric acid. Grade 3=severe and grade 4=potentially life threatening. Number of participants with grade 3 or 4 laboratory abnormalities is reported.
Time frame: From first dose of study treatment on Day 1 until Day 15
Number of Participants With Severe or Life-Threatening Bacterial, Invasive Fungal, or Opportunistic Infections Through Day 29
Number of participants with any severe or life-threatening bacterial, invasive fungal, or opportunistic infections through Day 29 is reported in this outcome measure. Severe= interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. Life threatening=Participant was at immediate risk of death from the event as it occurred; i.e., it did not include a reaction that if it had occurred in a more serious form might have caused death.
Time frame: Up to Day 29
Number of Participants With Intranasal Administration Reactions Through Day 29
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational product and that did not necessarily have a causal relationship with this treatment. Number of participants with any adverse events associated with intranasal administration were reported in this outcome measure.
Time frame: Up to Day 29
Percentage of Participants With >= 50% Reduction in Estimated Glomerular Filtration Rate (eGFR) From Baseline
Percentage of participants with \>=50% reduction in eGFR from Baseline during on-treatment phase were reported in this outcome measure.
Time frame: From Baseline (Day 1) up to Day 15
| Milestone | Zavegepant | Placebo |
|---|---|---|
| Started | 29 | 15 |
| Completed | 22 | 10 |
| Not completed | 7 | 5 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Death | 5 | 1 |
| Withdrew: Other | 0 | 2 |
| Withdrew: Randomized not treated | 1 | 0 |
The 6POSRS score was used to assess severity and ranged from 1 to 6 where: 1= Death; 2= Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO), 3= Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 4= Hospitalized, requiring supplemental oxygen; 5= Hospitalized, not requiring supplemental oxygen and 6= not hospitalized. A higher score indicated a better outcome.
| Units on a scale | Zavegepant | Placebo |
|---|---|---|
| Mean 6 Point Ordinal Severity Rating Scale (6POSRS) Score at Day 15 | 5.0 ± 1.81 | 4.5 ± 1.86 |
Percentage of participants who were alive and had a 6POSRS rating of 5 (Hospitalized, not requiring supplemental oxygen) or 6 (not hospitalized) and did not use supplemental oxygen at Day 29 were reported in this outcome measure. Participants with missing 6POSRS rating at Day 29 had the last on-study 6POSRS rating before Day 29 used. Participants with \>= 1 procedure day of supplemental oxygen use before Day 29 for an ongoing procedure were considered failures, i.e., not alive or not off of oxygen at Day 29. 95% confidence interval (CI) was based on exact Clopper and Pearson method.
| Percentage of participants | Zavegepant | Placebo |
|---|---|---|
| Percentage of Participants With a 6-Point Severity Rating of 5 or 6, Who Were Alive and Off Supplemental Oxygen at Day 29 | 67.9 (47.7 to 84.1) | 60.0 (32.3 to 83.7) |
Percentage of participants who had a 6POSRS rating of 2 (Hospitalized, on invasive mechanical ventilation or ECMO) or 3 (Hospitalized, on non-invasive ventilation or high-flow oxygen devices) or \>= 1 procedure day of ventilation or high-flow nasal cannula use on study through Day 29 were reported in this outcome measure. Participants with missing 6POSRS rating at Day 29 had all available on-study 6POSRS ratings before Day 29 used. 95% CI was based on exact Clopper and Pearson method.
| Percentage of participants | Zavegepant | Placebo |
|---|---|---|
| Percentage of Participants With a 6-Point Severity Rating of 2 or 3 or Required Initiation of Invasive Mechanical Ventilation, Non-Invasive Ventilation, or a High-Flow Nasal Cannula Through Day 29 | 46.4 (27.5 to 66.1) | 60.0 (32.3 to 83.7) |
Percentage of participants admitted into an ICU on any day through Day 29 were reported in this outcome measure. 95% CI was based on exact Clopper and Pearson method
| Percentage of participants | Zavegepant | Placebo |
|---|---|---|
| Percentage of Participants Admitted Into an Intensive Care Unit (ICU) Through Day 29 | 25.0 (10.7 to 44.9) | 20.0 (4.3 to 48.1) |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was any untoward medical occurrence that at any dose: resulted in death; was life-threatening; required prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect; other important medical events. Severe AEs were AEs that interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. On-treatment was defined as the time on study drug.
| Participants | Zavegepant | Placebo |
|---|---|---|
| Death | 1 | 1 |
| SAEs | 6 | 2 |
| Severe AEs | 7 | 3 |
The following laboratory parameters were assessed: eosinophils, hemoglobin, leukocytes, lymphocytes (high and low), neutrophils, platelets, alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium (high and low), creatine kinase, creatinine, glomerular filtration rate (GFR) estimated Modification of Diet in Renal Disease (MDRD), glucose (high and low), lactate dehydrogenase, potassium (high and low), sodium (high and low), urate, glucose (urine) and protein (urine). Laboratory abnormalities were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5 for all parameters except glucose and uric acid. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1 was used for grading glucose and uric acid. Grade 3=severe and grade 4=potentially life threatening. Number of participants with grade 3 or 4 laboratory abnormalities is reported.
| Participants | Zavegepant | Placebo |
|---|---|---|
| Eosinophils | 0 | 0 |
| Hemoglobin | 2 | 0 |
| Leukocytes | 0 | 0 |
| Lymphocytes, high | 0 | 0 |
| Lymphocytes, low | 3 | 3 |
| Neutrophils | 0 | 1 |
| Platelets | 0 | 0 |
| Alanine Aminotransferase | 0 | 0 |
| Albumin | 1 | 0 |
| Alkaline Phosphatase | 0 | 0 |
| Aspartate Aminotransferase | 0 | 0 |
| Bicarbonate | 0 | 0 |
| Bilirubin | 0 | 0 |
| Calcium, high | 0 | 0 |
| Calcium, low | 0 | 0 |
| Creatine Kinase | 1 | 0 |
| Creatinine | 1 | 1 |
| Glomerular Filtration Rate, Estimated MDRD | 1 | 1 |
| Glucose, high | 5 | 2 |
| Glucose, low | 0 | 0 |
| Lactate Dehydrogenase | 0 | 0 |
| Potassium, high | 0 | 0 |
| Potassium, low | 0 | 0 |
| Sodium, high | 0 | 0 |
| Sodium, low | 1 | 0 |
| Urate | 0 | 0 |
| Glucose, Urine | 0 | 0 |
| Protein, Urine | 0 | 0 |
Number of participants with any severe or life-threatening bacterial, invasive fungal, or opportunistic infections through Day 29 is reported in this outcome measure. Severe= interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. Life threatening=Participant was at immediate risk of death from the event as it occurred; i.e., it did not include a reaction that if it had occurred in a more serious form might have caused death.
| Participants | Zavegepant | Placebo |
|---|---|---|
| Number of Participants With Severe or Life-Threatening Bacterial, Invasive Fungal, or Opportunistic Infections Through Day 29 | 5 | 1 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational product and that did not necessarily have a causal relationship with this treatment. Number of participants with any adverse events associated with intranasal administration were reported in this outcome measure.
| Participants | Zavegepant | Placebo |
|---|---|---|
| Number of Participants With Intranasal Administration Reactions Through Day 29 | 16 | 3 |
Percentage of participants with \>=50% reduction in eGFR from Baseline during on-treatment phase were reported in this outcome measure.
| Percentage of participants | Zavegepant | Placebo |
|---|---|---|
| Percentage of Participants With >= 50% Reduction in Estimated Glomerular Filtration Rate (eGFR) From Baseline | 7.1 | 14.3 |
Collected over On treatment: From start of study drug on Day 1 up to Day 15 and Follow up: From Day 16 to Day 60. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zavegepant (On-treatment) | 1/28 (3.6%) | 6/28 (21.4%) | 22/28 (78.6%) |
| Placebo (On-treatment) | 1/15 (6.7%) | 2/15 (13.3%) | 13/15 (86.7%) |
| Zavegepant (Follow-up) | 4/27 (14.8%) | 2/27 (7.4%) | 4/27 (14.8%) |
| Placebo (Follow-up) | 0/13 (0%) | 1/13 (7.7%) | 2/13 (15.4%) |
| Event | Zavegepant (On-treatment) | Placebo (On-treatment) | Zavegepant (Follow-up) | Placebo (Follow-up) |
|---|---|---|---|---|
| Endotracheal intubationSurgical and medical procedures | 3/28 | 2/15 | 0/27 | 0/13 |
| Intensive careSurgical and medical procedures | 3/28 | 0/15 | 0/27 | 0/13 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 3/28 | 0/15 | 0/27 | 0/13 |
| Pneumonia bacterialInfections and infestations | 1/28 | 0/15 | 0/27 | 1/13 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/28 | 0/15 | 0/27 | 1/13 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/28 | 1/15 | 0/27 | 0/13 |
| SepsisInfections and infestations | 1/28 | 1/15 | 0/27 | 0/13 |
| Acute kidney injuryRenal and urinary disorders | 1/28 | 1/15 | 1/27 | 0/13 |
| BacteraemiaInfections and infestations | 0/28 | 0/15 | 1/27 | 0/13 |
| PneumoniaInfections and infestations | 0/28 | 0/15 | 1/27 | 0/13 |
| Event | Zavegepant (On-treatment) | Placebo (On-treatment) | Zavegepant (Follow-up) | Placebo (Follow-up) |
|---|---|---|---|---|
| DysgeusiaNervous system disorders | 16/28 | 1/15 | 0/27 | 0/13 |
| HyponatraemiaMetabolism and nutrition disorders | 4/28 | 5/15 | 0/27 | 0/13 |
| LeukocytosisBlood and lymphatic system disorders | 8/28 | 3/15 | 0/27 | 0/13 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 3/28 | 4/15 | 0/27 | 0/13 |
| AnaemiaBlood and lymphatic system disorders | 4/28 | 3/15 | 1/27 | 1/13 |
| Intensive careSurgical and medical procedures | 4/28 | 3/15 | 0/27 | 0/13 |
| HyperkalaemiaMetabolism and nutrition disorders | 5/28 | 2/15 | 0/27 | 0/13 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 3/28 | 2/15 | 0/27 | 2/13 |
| HeadacheNervous system disorders | 1/28 | 2/15 | 0/27 | 0/13 |
| HypermagnesaemiaMetabolism and nutrition disorders | 2/28 | 2/15 | 0/27 | 0/13 |
Safety analysis set included all participants who received \>=1 dose of study drug (zavegapant or placebo)
| Age, Continuous(Years) | Zavegepant | Placebo | Total |
|---|---|---|---|
| Mean | 53.0 ± 13.42 | 61.1 ± 12.41 | 55.8 ± 13.49 |
| Sex: Female, Male(Participants) | Zavegepant | Placebo | Total |
|---|---|---|---|
| Female | 11 | 5 | 16 |
| Male | 17 | 10 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Zavegepant | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 27 | 14 | 41 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Zavegepant | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 12 | 6 | 18 |
| White | 13 | 9 | 22 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Apr 2020 to primary completion in Apr 2022, 24 months.
Results were first posted in May 2024, 2 years after primary completion. A results delay was requested in Dec 2022.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zavegepant